Avacta Group (LON:AVCT) Posts Quarterly Earnings Results

Avacta Group (LON:AVCT) issued its quarterly earnings data on Wednesday. The biotechnology company reported GBX (4.23) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Avacta Group had a negative return on equity of 2,983.28% and a negative net margin of 34,584.96%.

Avacta Group Price Performance

Avacta Group stock traded up GBX 0.65 during mid-day trading on Wednesday, hitting GBX 72.65. 598,123 shares of the company were exchanged, compared to its average volume of 1,710,805. The company has a debt-to-equity ratio of 602.46, a current ratio of 0.89 and a quick ratio of 4.96. The company has a market capitalization of £340.40 million, a P/E ratio of -7.52 and a beta of 1.12. Avacta Group has a 12-month low of GBX 48 and a 12-month high of GBX 92. The business’s 50 day simple moving average is GBX 69.58 and its two-hundred day simple moving average is GBX 71.78.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).